Search results for "Treatment-Resistant"

showing 10 items of 19 documents

Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses

2021

AbstractTreatment resistance (TR) in patients with first-episode psychosis (FEP) is a major cause of disability and functional impairment, yet mechanisms underlying this severe disorder are poorly understood. As one view is that TR has neurodevelopmental roots, we investigated whether its emergence relates to disruptions in synchronized cortical maturation quantified using gyrification-based connectomes. Seventy patients with FEP evaluated at their first presentation to psychiatric services were followed up using clinical records for 4 years; of these, 17 (24.3%) met the definition of TR and 53 (75.7%) remained non-TR at 4 years. Structural MRI images were obtained within 5 weeks from first…

AdultAffective Disorders PsychoticMalePsychosisLongitudinal studymedicine.medical_specialtyAdolescentlongitudinalAcademicSubjects/MED00810treatment-resistantYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansLongitudinal Studiesfirst-episode psychosisGyrificationClozapineCerebral CortexFirst episodeclozapinebusiness.industryFunctional data analysisgyrificationmedicine.diseaseMagnetic Resonance Imaging030227 psychiatryschizophreniaPsychiatry and Mental healthPsychotic DisordersSchizophreniaConnectomeCardiologyFemaleNerve Netbusiness030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up StudiesRegular ArticlesMRImedicine.drugSchizophrenia Bulletin
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression : Baseline patient characteristics

2021

Journal of affective disorders 283, 115-122 (2021). doi:10.1016/j.jad.2020.11.124

AdultMaleDisease burden; Health-related quality of life; Major depressive disorder; Observational study; Patient-reported outcomes; Socio-economic status; Adult; Cohort Studies; Europe; Female; Humans; Male; Middle Aged; Quality of Life; Depressive Disorder Major; Depressive Disorder Treatment-Resistantmedicine.medical_specialtyHealth-related quality of lifeSocio-economic statusMajor depressive disorderCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineQuality of lifeObservational studyInternal medicinemedicineHumansMedical historyDepression (differential diagnoses)Disease burdenDepressive DisorderDepressive Disorder MajorPatient-reported outcomesDisease burden Health-related quality of life Major depressive disorder Observational study Patient-reported outcomes Socio-economic statusbusiness.industryTreatment-ResistantMajorDisease burdenMiddle Agedmedicine.disease030227 psychiatry3. Good healthEuropePsychiatry and Mental healthClinical PsychologyPresenteeismQuality of LifeMajor depressive disorderFemalebusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort study
researchProduct

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial

2015

Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy…

AdultMalemedicine.medical_specialtyAdolescentCitalopramLithiumCitalopramlaw.inventionDepressive Disorder Treatment-ResistantYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawEarly Medical InterventionInternal medicinemedicineHumansEscitalopramPharmacology (medical)PsychiatryBiological PsychiatryAgedPharmacologyVenlafaxine HydrochlorideGuidelineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeNeurologyDelayed-Action PreparationsAntidepressive Agents Second-GenerationAntidepressantMajor depressive disorderDrug Therapy CombinationFemaleNeurology (clinical)Psychology030217 neurology & neurosurgerymedicine.drugEuropean Neuropsychopharmacology
researchProduct

Clinical Predictors of Response to Magnetic Seizure Therapy in Depression

2019

Objectives Magnetic seizure therapy (MST) is a novel convulsive brain stimulation method in clinical testing, which is used as an alternative for electroconvulsive therapy in patients with treatment-resistant depression (TRD). Preliminary studies have suggested that MST leads to fewer cognitive adverse effects than electroconvulsive therapy but has similar efficacy. However, the clinical predictors of response to MST have not been evaluated yet. This study aimed to investigate whether these predictors can be identified in patients with TRD. Methods Thirty-eight patients with TRD were included. As clinical predictors for treatment response, we used the diagnosis, sex, age, family history, an…

AdultMalemedicine.medical_specialtyAnhedoniaMagnetic Field Therapymedicine.medical_treatmentNeuroscience (miscellaneous)Depressive Disorder Treatment-Resistant03 medical and health sciences0302 clinical medicineElectroconvulsive therapyPredictive Value of TestsSeizuresInternal medicinemedicineHumansFamily historyAtypical depressionDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressionbusiness.industryHamilton Rating Scale for DepressionMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthTreatment OutcomeMagnetic seizure therapyBrain stimulationAnxietyFemalemedicine.symptombusinesshuman activities030217 neurology & neurosurgeryThe Journal of ECT
researchProduct

Effects of magnetic seizure therapy on anterograde and retrograde amnesia in treatment‐resistant depression

2019

Background Electroconvulsive therapy (ECT) is the gold standard for treatment-resistant depression (TRD). However, cognitive side effects, mainly anterograde and retrograde amnesia, frequently occur. Magnetic seizure therapy (MST) is tested using more focal seizure induction. However, the suggestion MST may be more beneficial than ECT because it causes fewer amnesia have not yet been comprehensively investigated using common neuropsychological testing specifically for ECT. We aimed to examine whether MST causes anterograde and retrograde amnesia. Methods Ten patients with TRD were treated with MST (8.9 [2] treatments) at 100% machine output, a frequency of 100 Hz and 657.4 (62) pulses per t…

AdultMalemedicine.medical_specialtyAnterograde amnesiamedicine.medical_treatmentAmnesiaNeuropsychological TestsAudiologybehavioral disciplines and activitiesDepressive Disorder Treatment-ResistantExecutive Function03 medical and health sciences0302 clinical medicineElectroconvulsive therapySeizuresmental disordersmedicineHumansElectroconvulsive Therapymedicine.diagnostic_testbusiness.industryRetrograde amnesiaNeuropsychological testMiddle AgedAmnesia Anterogrademedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyMagnetic FieldsMagnetic seizure therapyBrain stimulationMental RecallAmnesia RetrogradeFemalemedicine.symptombusinesshuman activitiesTreatment-resistant depression030217 neurology & neurosurgeryDepression and Anxiety
researchProduct

Interest of targeting either cortical area Brodmann 9 or 46 in rTMS treatment for depression: a preliminary randomized study.

2013

Abstract Objective To assess the interest of specifically targeting Brodmann Areas (BA) 9 or 46 for rTMS treatment of depression. Methods Patients with Treatment-Resistant Depression were randomly assigned to two treatment groups to receive either rTMS on BA 9 or on BA 46. Each patient underwent 10 sessions of 1Hz-rTMS for 2weeks. The Hamilton and Montgomery–Asberg Depression Rating Scales (HDRS, MADRS) were used under blind conditions to assess the therapeutic response (50% improvement). A Wilcoxon signed-rank test was used to compare the depression rating scales scores obtained before and after the 10 rTMS sessions for each of the two groups. The therapeutic results in the two groups were…

AdultMalemedicine.medical_specialtyWilcoxon signed-rank testAudiologybehavioral disciplines and activitieslaw.inventionDepressive Disorder Treatment-ResistantRandomized controlled trialRating scalelawPhysiology (medical)medicineHumansPsychiatryDepression (differential diagnoses)AgedCerebral CortexBrain MappingMiddle AgedTranscranial Magnetic StimulationSensory SystemsDorsolateral prefrontal cortexmedicine.anatomical_structureNeurologyFemaleNeurology (clinical)PsychologyClinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
researchProduct

Degree of Postictal Suppression Depends on Seizure Induction Time in Magnetic Seizure Therapy and Electroconvulsive Therapy.

2017

OBJECTIVES Anesthesia is required for both magnetic seizure therapy (MST) and electroconvulsive therapy (ECT), although it has anticonvulsant properties. In this case, bispectral index (BIS) monitoring, a specific electroencephalogram-derived monitoring, can be used to find the optimal seizure induction time during anesthesia to elicit adequate seizures. A measurement of seizure adequacy in electroencephalogram is the postictal suppression. The purpose of this study was to investigate the influence of seizure induction time on the degree of postictal suppression by comparing BIS versus no-BIS monitoring in MST and ECT. METHODS Twenty patients with treatment-resistant depression were randoml…

AdultMalemedicine.medical_treatmentNeuroscience (miscellaneous)law.invention03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineElectroconvulsive therapyConsciousness MonitorsElectromagnetic FieldsRandomized controlled triallawPredictive Value of TestsSeizuresmedicineHumansAnesthesiaProspective StudiesElectroconvulsive TherapyAgedPsychiatric Status Rating ScalesCross-Over Studiesbusiness.industryElectroencephalographyMiddle AgedCrossover study030227 psychiatryPsychiatry and Mental healthAnticonvulsantTreatment OutcomeMagnetic seizure therapyBispectral indexAnesthesiaBrain stimulationFemaleAnalysis of variancebusinesshuman activities030217 neurology & neurosurgeryThe journal of ECT
researchProduct

PMH2 Treatment Outcomes for Patients with Treatment Resistant Depression in European Standard Clinical Practice

2020

Clinical Practicemedicine.medical_specialtybusiness.industryHealth PolicyTreatment outcomePublic Health Environmental and Occupational HealthmedicineEuropean standardmedicine.diseaseIntensive care medicinebusinessTreatment-resistant depressionValue in Health
researchProduct

Grey matter microstructural alterations in schizophrenia patients with treatment-resistant auditory verbal hallucinations.

2021

Treatment-resistant auditory verbal hallucinations (TRAVH) are a relatively prevalent and devastating symptom in patients with schizophrenia (SCZ). Even though their pathological mechanisms are poorly understood, they seem to differ from those underlying non-hallucinating SCZ.& nbsp; In this study, we characterise structural brain changes in SCZ patients with TRAVH. With respect to nonhallucinating patients and healthy controls, we studied macrostructural grey matter changes through cortical thickness and subcortical volumetric data. Additionally, we analysed microstructural differences across groups using intracortical and subcortical mean diffusivity data. This latter imaging metric has b…

Deep brain stimulationHallucinationsmedicine.medical_treatmentHippocampusAuditory hallucinationsGrey matterHippocampusCortical thickness03 medical and health sciences0302 clinical medicineMean diffusivityMedicineHumansIn patientClinical severityGray MatterTreatment resistantPathologicalBiological Psychiatrybusiness.industryBrainmedicine.diseaseMagnetic Resonance Imaging030227 psychiatryPsychiatry and Mental healthmedicine.anatomical_structureSchizophreniaTreatment-resistantSchizophreniabusinessNeuroscience030217 neurology & neurosurgeryJournal of psychiatric research
researchProduct

Childhood Trauma increases suicidal behaviour in a treatment-resistant depression population: a FACE-DR report

2021

International audience; Objective: In addition to heredity, exposure to early-life adversity is an important predisposing risk factor of suicidal behaviour. Although the association between Childhood Trauma (CT) and suicide risk is well documented, interactions between CT and suicidal behaviour in Treatment-Resistant Depression (TRD) populations have received little coverage. This study aimed to evaluate i) association between CT and suicidal behaviour in a TRD population, and ii) the role of personality traits and impulsiveness as potential factors of mediation in these associations.Methods: Patients were recruited from a cohort of the French network of TRD expert centers. Depressive sympt…

Depressive disordersMESH: DepressionMESH: ViolencePopulationPoison controlViolenceSuicide preventionChildhood traumaMESH: Depressive Disorder Treatment-ResistantSuicidal IdeationDepressive Disorder Treatment-Resistant03 medical and health sciences0302 clinical medicineMESH: Risk FactorsRisk FactorsRating scaleSurveys and QuestionnairesHumansMedicineMESH: Surveys and QuestionnairesRisk factoreducationSuicidal ideationChildhood neglectBiological Psychiatryeducation.field_of_studyMESH: HumansMESH: Suicidal IdeationDepressionbusiness.industryChildhood abuseCTQ tree3. Good health030227 psychiatrySuicidePsychiatry and Mental health[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthTreatment-resistant depressionmedicine.symptomColumbia Suicide Severity Rating Scalebusiness030217 neurology & neurosurgeryClinical psychology
researchProduct